Last reviewed · How we verify
EOC202
EOC202 is a small molecule that targets the SGLT2 receptor.
EOC202 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | EOC202 |
|---|---|
| Sponsor | Taizhou EOC Pharma Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, EOC202 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy (PHASE2)
- Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EOC202 CI brief — competitive landscape report
- EOC202 updates RSS · CI watch RSS
- Taizhou EOC Pharma Co., Ltd. portfolio CI